Alessandra Ciucci

Rome, 00168, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer.

Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: September 08, 2025

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer.

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer.

Journal: Cancers

Published: March 03, 2023

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.

Journal: Journal of experimental & clinical cancer research : CR

Published: February 21, 2023

What's beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study.

What's beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study.

Journal: Cancers

Published: September 01, 2022

Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.

Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.

Journal: Cellular and molecular life sciences : CMLS

Published: March 17, 2022

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 19, 2021

Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study.

Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study.

Journal: Cancers

Published: September 17, 2021

In search for biomarkers and potential drug targets for uterine serous endometrial cancer.

In search for biomarkers and potential drug targets for uterine serous endometrial cancer.

Journal: Journal of cancer research and clinical oncology

Published: January 19, 2021

KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer.

KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 17, 2020

Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer.

Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer.

Journal: Cancers

Published: March 17, 2020

Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4.

Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4.

Journal: Cancers

Published: July 12, 2019

A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer.

A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 26, 2019

Showing 1-12 of 23

Last Updated: 09/26/2026